Vertex, once king of hep C category, bows out as new drugs eclipse Incivek

Biotech Vertex ($VRTX) has pulled the plug on work in the hepatitis C arena, an area it was expected to dominate with its Incivek until Gilead Sciences ($GILD) redefined the category with Sovaldi, a drug now expected to become the top seller of all time. Even with Incivek fading away, Vertex has continued work in the area, but yesterday said it would out-license its remaining hep C drug, VX-135, and focus its efforts on cystic fibrosis, FierceBiotech reports. Story | More

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.